Celldex Therapeutics Inc. (CLDX): Price and Financial Metrics
CLDX Price/Volume Stats
| Current price | $19.53 | 52-week high | $47.00 |
| Prev. close | $19.67 | 52-week low | $14.40 |
| Day low | $19.25 | Volume | 667,700 |
| Day high | $19.77 | Avg. volume | 885,075 |
| 50-day MA | $19.05 | Dividend yield | N/A |
| 200-day MA | $25.70 | Market Cap | 1.30B |
CLDX Stock Price Chart Interactive Chart >
Celldex Therapeutics Inc. (CLDX) Company Bio
Celldex Therapeutics Inc is a biopharmaceutical company. Celldex was formed in 2005 from a spin-off of the New Jersey based biopharmaceutical company Medarex. The company is engaged in the development and commercialization of immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. Celldex is dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. The company’s drug pipeline includes antibody-based therapeutics which can engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. The company is headquartered in Hampton, New Jersey and has other operational facilities in Massachusetts and Connecticut. Anthony S. Marucci, one of Celldex’s founders, serves as Chief Executive Officer, President, and Director.
CLDX Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLDX Price Returns
| 1-mo | 3.28% |
| 3-mo | -5.52% |
| 6-mo | -27.05% |
| 1-year | -44.37% |
| 3-year | -20.58% |
| 5-year | 534.09% |
| YTD | -22.71% |
| 2024 | -36.28% |
| 2023 | -11.02% |
| 2022 | 15.35% |
| 2021 | 120.55% |
| 2020 | 685.65% |